Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melanoderm 4% Cream for the treatment of facial melasma: randomized split-face study
2013-003501-25Phase 3Active
- Sponsor
- mesoestetic Pharma Group
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of hydroquinone in melasma (2 arms), sponsored by mesoestetic Pharma Group. Primary endpoint: MASI Index. Started Nov 2013; status: active.
02
Drugs
hydroquinone
03
Conditions
melasma
Beyond the preview
Go deeper on 2013-003501-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003501-25.